TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury
Brief Summary: The purpose of the study is to explore to what extent continuing the antidepressant medication citalopram (Celexa), after depression has responded to treatment, helps prevent the return of depressive symptoms in patients with recent traumatic brain injury (TBI).


Options:
A: Intervention Type: DRUG; Name: Ebixa (memantine hydrochloride); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cipralex (escitalopram); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A
C: Arm Label: Citalopram + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pindolol | Arm Label: Citalopram + pindolol; Type: EXPERIMENTAL; Interventions: Drug: Pindolol | Intervention Type: DRUG; Name: Pindolol; Assigned to Arm(s): Citalopram + pindolol, Citalopram + placebo
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: citalopram | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Prospective, Double-Blinded, Placebo-Controlled (Sham-Controlled) Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of the Adacolumn Apheresis System as a treatment for the signs and symptoms of Crohn's disease.


Options:
A: Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, sugar pill | Arm Label: Naltrexone; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone | Intervention Type: OTHER; Name: Placebo, sugar pill; Assigned to Arm(s): Sugar pill
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: adalimumab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: ciprofloxacin | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ciprofloxacin; Assigned to Arm(s): 2
C: Arm Label: Adacolumn; Type: ACTIVE_COMPARATOR; Interventions: Device: Adacolumn | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: Adacolumn; Assigned to Arm(s): Adacolumn | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham
D: Arm Label: Tight Control Management; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Prednisone, Drug: Azathioprine | Arm Label: Clinically Driven Management; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab, Drug: Prednisone, Drug: Azathioprine | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Clinically Driven Management, Tight Control Management | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Clinically Driven Management, Tight Control Management | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Clinically Driven Management, Tight Control Management

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Adenotomy and Tympanostomy on Preventing Recurrent Otitis Media in the Young Children
Brief Summary: The purpose of this study is to find out if young children have more benefit of the combination of adenotomy and tympanostomy than plain tympanostomy in prevention of recurrent otitis media.


Options:
A: Arm Label: Ventilation tube treatment; Type: EXPERIMENTAL; Interventions: Device: Ventilation tube treatment | Arm Label: Conservative treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Ventilation tube treatment; Assigned to Arm(s): Ventilation tube treatment
B: Arm Label: Wait and watch (Group D); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Mometasone spray (Group B); Type: EXPERIMENTAL; Interventions: Drug: Mometasone 50 Mcg/Inh Nasal Spray | Arm Label: antibiotic + histaminic + oxymetazoline drops (Group A); Type: EXPERIMENTAL; Interventions: Drug: Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%) | Arm Label: Oral steroid (Group C); Type: EXPERIMENTAL; Interventions: Drug: Steroid Drug (prednisolone) | Intervention Type: DRUG; Name: Mometasone 50 Mcg/Inh Nasal Spray; Assigned to Arm(s): Mometasone spray (Group B) | Intervention Type: DRUG; Name: Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%); Assigned to Arm(s): antibiotic + histaminic + oxymetazoline drops (Group A) | Intervention Type: DRUG; Name: Steroid Drug (prednisolone); Assigned to Arm(s): Oral steroid (Group C)
C: Intervention Type: PROCEDURE; Name: Insertion of tympanostomy tubes; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: adenoidectomy and tymapanostomy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Adenotomy and Tympanostomy on Preventing Recurrent Otitis Media in the Young Children
Brief Summary: The purpose of this study is to find out if young children have more benefit of the combination of adenotomy and tympanostomy than plain tympanostomy in prevention of recurrent otitis media.


Options:
A: Arm Label: Ventilation tube treatment; Type: EXPERIMENTAL; Interventions: Device: Ventilation tube treatment | Arm Label: Conservative treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Ventilation tube treatment; Assigned to Arm(s): Ventilation tube treatment
B: Intervention Type: PROCEDURE; Name: adenoidectomy and tymapanostomy; Assigned to Arm(s): N/A
C: Arm Label: Montelukast; Type: EXPERIMENTAL; Interventions: Drug: Monteleukast | Arm Label: Mometasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Monteleukast; Assigned to Arm(s): Montelukast | Intervention Type: DRUG; Name: Mometasone; Assigned to Arm(s): Mometasone
D: Intervention Type: PROCEDURE; Name: Insertion of tympanostomy tubes; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lacunar-Brain Infarction Cerebral Hyperactivity And Atorvastatin Trial. A Placebo-Controlled Trial Of High-Dose Atorvastatin In Patients With Cerebral Small Vessel Disease.
Brief Summary: The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.


Options:
A: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
B: Arm Label: atorvastatin 10 mg, 80 mg; Type: EXPERIMENTAL; Interventions: Drug: statin | Intervention Type: DRUG; Name: statin; Assigned to Arm(s): atorvastatin 10 mg, 80 mg
C: Intervention Type: PROCEDURE; Name: Blood samples; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized Double-Blind Study Comparing The Pleiotropic Effects Of Atorvastatin 10 Mg And 80 Mg Over A 26-Week Period In Subjects With Coronary Atherosclerosis
Brief Summary: The primary objective of the study is to evaluate the efficacy of atorvastatin 80 mg daily as compared to atorvastatin 10 mg daily in reducing C-reactive protein levels over a 26-week treatment period in subjects with documented coronary artery disease.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550, Drug: Atorvastatin | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550, Drug: Atorvastatin Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Atorvastatin Placebo; Assigned to Arm(s): Arm 2
B: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Blood samples; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: LCP-AtorFen; Type: EXPERIMENTAL; Interventions: Drug: LCP-AtorFen | Arm Label: atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: atorvastatin | Arm Label: fenofibrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: fenofibrate | Intervention Type: DRUG; Name: LCP-AtorFen; Assigned to Arm(s): LCP-AtorFen | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): atorvastatin | Intervention Type: DRUG; Name: fenofibrate; Assigned to Arm(s): fenofibrate

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Follow-up Management of Peripheral Arterial Intervention With Clopidogrel MIRROR-Study
Brief Summary: The Mirror Study is a randomized, double-blinded mono-centre trial the access the periinterventinal and postinterventional administration of clopidogrel in patients with peripheral vascular disease.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin Tablets | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel (over encapsulated) capsule, Drug: Aspirin Tablets | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor Tablets, Drug: Aspirin Tablets | Intervention Type: DRUG; Name: Ticagrelor Tablets; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Clopidogrel (over encapsulated) capsule; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Aspirin Tablets; Assigned to Arm(s): 1, 2, 3
B: Arm Label: ASS + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: clopidogrel | Arm Label: ASS + Plavix; Type: ACTIVE_COMPARATOR; Interventions: Drug: clopidogrel | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): ASS + Placebo, ASS + Plavix
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: clopidogrel and aspirin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin | Intervention Type: DRUG; Name: clopidogrel and aspirin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): 2
D: Arm Label: Endeavor arm; Type: EXPERIMENTAL; Interventions: Device: Zotarolimus-eluting stent | Arm Label: Endeavor resolute arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Zotarolimus-eluting stent for ACS and DM | Arm Label: Xience arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Everolimus-eluting stent for long lesion | Arm Label: Cypher arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Sirolimus-eluting stent for short lesion | Intervention Type: DEVICE; Name: Zotarolimus-eluting stent; Assigned to Arm(s): Endeavor arm | Intervention Type: DEVICE; Name: Zotarolimus-eluting stent for ACS and DM; Assigned to Arm(s): Endeavor resolute arm | Intervention Type: DEVICE; Name: Everolimus-eluting stent for long lesion; Assigned to Arm(s): Xience arm | Intervention Type: DEVICE; Name: Sirolimus-eluting stent for short lesion; Assigned to Arm(s): Cypher arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Ciclesonide and of a Fixed Combination With Fluticasone Propionate and Salmeterol Versus Placebo on Long-term Asthma Control
Brief Summary: The aim of the study is to compare the efficacy of ciclesonide versus fixed combination of fluticasone propionate/salmeterol versus placebo, on long-term asthma control in patients with mild persistent asthma. The study duration consists of a baseline period (2 weeks) and a treatment period (12 months). The study will provide further data on safety and tolerability of ciclesonide.


Options:
A: Intervention Type: DRUG; Name: ciclesonide; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Ciclesonide (XRP1526); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): N/A
D: Arm Label: Ciclesonide 40 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 80 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 160 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Salbutamol | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BALLOON: Efficacy and Safety - Study by ALTANA on Ciclesonide in Pre-school Asthma Patients
Brief Summary: The aim of the present study is to compare the efficacy of inhaled ciclesonide in pre-school children. Ciclesonide will be inhaled once daily, using one of three dose levels and tested versus placebo. The study duration consists of a baseline period (2 to 4 weeks) and a treatment period (24 weeks). The study will provide further data on safety and tolerability of ciclesonide.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: BDA MDI (PT027) 160/180 μg; Type: EXPERIMENTAL; Interventions: Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg | Arm Label: BDA MDI (PT027) 80/180 μg; Type: EXPERIMENTAL; Interventions: Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg | Arm Label: AS MDI (PT007) 180 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albuterol sulfate metered-dose inhaler 180 μg | Intervention Type: COMBINATION_PRODUCT; Name: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg; Assigned to Arm(s): BDA MDI (PT027) 160/180 μg | Intervention Type: COMBINATION_PRODUCT; Name: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg; Assigned to Arm(s): BDA MDI (PT027) 80/180 μg | Intervention Type: DRUG; Name: Albuterol sulfate metered-dose inhaler 180 μg; Assigned to Arm(s): AS MDI (PT007) 180 µg
C: Arm Label: PARTICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: PARTICS using QVAR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: PARTICS using QVAR; Assigned to Arm(s): PARTICS
D: Arm Label: steroid; Type: ACTIVE_COMPARATOR; Interventions: Drug: prednisolone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: prednisolone | Intervention Type: DRUG; Name: prednisolone; Assigned to Arm(s): placebo, steroid

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BALLOON: Efficacy and Safety - Study by ALTANA on Ciclesonide in Pre-school Asthma Patients
Brief Summary: The aim of the present study is to compare the efficacy of inhaled ciclesonide in pre-school children. Ciclesonide will be inhaled once daily, using one of three dose levels and tested versus placebo. The study duration consists of a baseline period (2 to 4 weeks) and a treatment period (24 weeks). The study will provide further data on safety and tolerability of ciclesonide.


Options:
A: Intervention Type: BEHAVIORAL; Name: Home-based adherence monitoring; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
C: Arm Label: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg | Arm Label: fluticasone propionate 2 x 100 mcg; Type: OTHER; Interventions: Drug: fluticasone propionate 2 x 100 mcg | Intervention Type: DRUG; Name: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg; Assigned to Arm(s): Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg | Intervention Type: DRUG; Name: fluticasone propionate 2 x 100 mcg; Assigned to Arm(s): fluticasone propionate 2 x 100 mcg
D: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BALLOON: Efficacy and Safety - Study by ALTANA on Ciclesonide in Pre-school Asthma Patients
Brief Summary: The aim of the present study is to compare the efficacy of inhaled ciclesonide in pre-school children. Ciclesonide will be inhaled once daily, using one of three dose levels and tested versus placebo. The study duration consists of a baseline period (2 to 4 weeks) and a treatment period (24 weeks). The study will provide further data on safety and tolerability of ciclesonide.


Options:
A: Intervention Type: DRUG; Name: ciclesonide; Assigned to Arm(s): N/A
B: Arm Label: Daily ICS + Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Daily ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albuterol sulfate | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS + Rescue ICS, Rescue ICS | Intervention Type: DRUG; Name: Albuterol sulfate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS, Placebo, Rescue ICS
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
D: Arm Label: 1 Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Arm Label: 2 Nedocromil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nedocromil | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 Placebo | Intervention Type: DRUG; Name: Nedocromil; Assigned to Arm(s): 2 Nedocromil | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): 1 Budesonide

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trauma Reception and Resuscitation Project - 'Time for a New Approach'
Brief Summary: Test the hypothesis that the implementation of real-time, computer-prompted algorithms in the first half hour of trauma management will result in a measurable reduction in management errors associated with the reception and resuscitation of major trauma patients.

Demonstrate that a reduction in management errors will translate into a reduction in morbidity and mortality.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: STOPP Criteria Decision Support Content | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: STOPP Criteria Decision Support Content; Assigned to Arm(s): Intervention
B: Intervention Type: DEVICE; Name: Real time computer prompted trauma algorithms; Assigned to Arm(s): N/A
C: Arm Label: Non-Physician Provider; Type: EXPERIMENTAL; Interventions: Other: Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Primary Care Provider; Type: ACTIVE_COMPARATOR; Interventions: Other: Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment | Intervention Type: OTHER; Name: Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment; Assigned to Arm(s): Non-Physician Provider, Primary Care Provider
D: Arm Label: Receive CDS intervention; Type: EXPERIMENTAL; Interventions: Other: MAPLE | Arm Label: No CDS intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: MAPLE; Assigned to Arm(s): Receive CDS intervention

Answer: B